Drugs / JCXH-221
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05743335 | Mar → Dec 2023 | COVID-19 | Immorna Biotherapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JCXH-221 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05743335 ↗ |